Compare Charles River Laboratories Intl. Inc (CRL) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Intuitive Surgical, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $281.43 (market cap $13.46B), while Intuitive Surgical, Inc. trades at $401.05 (market cap $141.75B). The key difference: Intuitive Surgical, Inc. is far larger — about 10.5× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| CRL | ISRG | |
|---|---|---|
Market Cap | $13.46B | $141.75B |
Sector | Health | Health |
52-Week High | $282.00 | $592.85 |
52-Week Low | $145.57 | $332.02 |
Enterprise Value | $16.30B | $136.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
Intuitive Surgical (ISRG) trades at $401.46, up 2.05% today, with strong quarterly earnings beats and bullish analyst consensus. The stock shows robust revenue growth, expanding margins, and solid cash flow, supported by the da Vinci 5 system adoption. Technical indicators are mixed, with RSI signaling overbought conditions but moving averages bullish.
Outlook remains positive due to durable demand and innovation, though high valuation and competition pose risks. Upside to the $518.10 consensus target offers potential, but investors should weigh premium multiples against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
